Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryo-milling

被引:50
作者
Chieng, Norman [1 ]
Rades, Thomas [1 ]
Saville, Dorothy [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
关键词
ranitidine hydrochloride; cryo-milling; amorphous; stability; polymorphic transformation; seeding; glass transition; crystallization temperature;
D O I
10.1016/j.ejpb.2007.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of cryo-milling on ranitidine hydrochloride polymorphs form I and 2 was investigated with particular interest in the formation and the stability of the amorphous phase. Cryo-milling was carried out using an oscillatory ball mill for periods up to 60 min, with re-cooling of the milling chamber with liquid nitrogen at 15 min intervals. Results showed that both ranitidine hydrochloride form I and form 2 could be fully converted to the amorphous form as determined by XRPD within 30 min. Upon 14 days storage, the amorphous samples crystallized back to their original forms. In the stability studies of amorphous drug with seeds, significant polymorphic transformation from form I to form 2 was not found when amorphous form prepared from form I was seeded with form 2 crystals by gentle physical mixing. In contrast, amorphous form prepared from form 1 seeded with form 2 crystals by ball milling for I min and simultaneous cryo-milling methods were found to transform amorphous form prepared from form I to crystalline form 2 under some storage conditions. The transformation was thought to be facilitated by interaction between seed crystals and amorphous drug and a storage temperature above the Tg. Amorphous form prepared from form 2 did not transform to crystalline form I under any conditions used in this study. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:771 / 780
页数:10
相关论文
共 14 条
[1]   Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride [J].
Agatonovic-Kustrin, S ;
Wu, V ;
Rades, T ;
Saville, D ;
Tucker, IG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 184 (01) :107-114
[2]  
Bernstein J., 2002, POLYMORPHISM MOL CRY, P1
[3]   Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1 [J].
Chieng, N. ;
Zujovic, Z. ;
Bowmaker, G. ;
Rades, T. ;
Saville, D. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 327 (1-2) :36-44
[4]  
CROWLEY K, 2001, J PHARM SCI, V92, P492
[5]  
DUNKEL U, 2003, P ANN C AUSTR PHARM
[6]  
FORSTER A, 1998, INT J VIBRAT SPECTRO, V2
[7]   PREPARATION AND CHARACTERIZATION OF RANITIDINE-HCL CRYSTALS [J].
MADAN, T ;
KAKKAR, AP .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (09) :1571-1588
[8]   Solubility, dissolution rate and phase transition studies of ranitidine hydrochloride tautomeric forms [J].
Mirmehrabi, M ;
Rohani, S ;
Murthy, KSK ;
Radatus, B .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 282 (1-2) :73-85
[9]   Characterization of tautomeric forms of ranitidine hydrochloride: thermal analysis, solid-state NMR, X-ray [J].
Mirmehrabi, M ;
Rohani, S ;
Murthy, KSK ;
Radatus, B .
JOURNAL OF CRYSTAL GROWTH, 2004, 260 (3-4) :517-526
[10]   Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by Raman spectroscopy and principal components analysis [J].
Pratiwi, D ;
Fawcett, JP ;
Gordon, KC ;
Rades, T .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (03) :337-341